

Hemovigilance Module Adverse Reaction Delayed Serologic Transfusion Reaction

*Required for saving	
*Facility ID#: NHSN Adverse Reaction #:	
Patient Information	
*Patient ID: *Date of Birth:/	_/
*Sex at Birth: DM DF DUnknown *Gender Identity (Specif	ify):
Social Security #: Secondary ID: Medicare #:	
Last Name: First Name: Middle Name:	
Ethnicity 🗌 Hispanic or Latino 🗌 Not Hispanic or Not Latino	
Race American Indian/Alaska Native Asian Black or African American	
Native Hawaiian/Other Pacific Islander White	
*Blood Group: A- A+ B- B+ AB- AB+ O- O+ Blood type	not done
Transitional ABO / Rh + Transitional ABO / Rh - Transitional ABO / Th	ransitional Rh
Group A/Transitional Rh 🗌 Group B/Transitional Rh 🗌 Group O/Transitional Rh 🗌 Group AB/Tra	ansitional Rh
Patient Medical History	
List the patient's admitting diagnosis. (Use ICD-10 Diagnostic codes/descriptions)	
Code: Description:	
Code: Description:	
Code: Description:	
List the patient's underlying indication for transfusion. (Use ICD-10 Diagnostic codes/descriptions)	
Code: Description:	
Code: Description:	
Code: Description:	
	UNKNOWN NONE
Code: Description:	
Code: Description:	
Code: Description:	
Assurance of Confidentiality: The voluntarily provided information obtained in this surveillance system that would permit identification of institution is collected with a guarantee that it will be held in strict confidence, will be used only for the purposes stated, and will not othe disclosed or released without the consent of the individual, or the institution in accordance with Sections 304, 306 and 308(d) of the Purpose Service Act (42 USC 242b, 242k, and 242m(d)).	nerwise be
Public reporting burden of this collection of information is estimated to average 20 minutes per response, including the time for reviewing searching existing data sources, gathering, and maintaining the data needed, and completing and reviewing the collection of information may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OI number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for burden to CDC, Reports Clearance Officer, 1600 Clifton Rd., MS H21-8, Atlanta, GA 30333, ATTN: PRA (0920-0666).	on. An agency MB control



	dical procedure including past p hospital or outpatient stay. <i>(Use</i>		to be
Code:	Description:		
Code:	Description:		
Code:	Description:		
Additional Information			
Transfusion History			
Blood Product:	evious transfusion? VB	☐ YES ☐ NO] Plasma ☐ Cryoprecip)WN ☐ YES ☐	UNKNOWN bitate Granulocyte
If yes, provide information a Type of transfusion adverse HTR TTI	about the transfusion adverse re	action.] AHTR	_] DSTR □ FNHTR LI □ UNKNOWN
Reaction Details			
*Date reaction occurred:/	/ *Time reaction occ	urred::	Time unknown
*Facility location where patier			
Is this reaction associated with a	an incident?	No If Yes, Incident	#:
Investigation Desults			
Investigation Results			
* Delayed serologic tran	sfusion reaction (DSTR)		
* Delayed serologic tran Antibody(ies):	ck all that apply: gns of hemolysis	against red blood cells	
* Delayed serologic tran Antibody(ies):	ck all that apply: gns of hemolysis pulin test (DAT) , clinically-significant antibodies en with newly identified RBC all	against red blood cells	
 * Delayed serologic tran Antibody(ies):	ck all that apply: gns of hemolysis pulin test (DAT) , clinically-significant antibodies en with newly identified RBC all	against red blood cells	□ Nausea/vomiting
* Delayed serologic tran Antibody(ies):	ck all that apply: gns of hemolysis pulin test (DAT) , clinically-significant antibodies en with newly identified RBC all (check all that apply)	against red blood cells oantibody	Nausea/vomiting
* Delayed serologic tran Antibody(ies):	ck all that apply: gns of hemolysis pulin test (DAT) , clinically-significant antibodies en with newly identified RBC all (check all that apply)	against red blood cells oantibody	□ Nausea/vomiting □ Jaundice □ Urticaria (hives)
* Delayed serologic tran Antibody(ies):	ck all that apply: gns of hemolysis pulin test (DAT) , clinically-significant antibodies en with newly identified RBC all (check all that apply) Chills/rigors Blood pressure decrease Edema	against red blood cells oantibody Fever Shock Flushing Pruritus (itching)	Jaundice
* Delayed serologic tran Antibody(ies):	ck all that apply: gns of hemolysis pulin test (DAT) , clinically-significant antibodies en with newly identified RBC all (check all that apply) Chills/rigors Blood pressure decrease Edema Other rash	against red blood cells oantibody Fever Shock Flushing Pruritus (itching)	☐ Jaundice ☐ Urticaria (hives)
* Delayed serologic tran Antibody(ies):	ck all that apply: gns of hemolysis pulin test (DAT) , clinically-significant antibodies en with newly identified RBC all (check all that apply) Chills/rigors Blood pressure decrease Edema Other rash	against red blood cells oantibody Fever Shock Flushing Pruritus (itching) coagulation Hemogl	☐ Jaundice ☐ Urticaria (hives) obinemia
* Delayed serologic tran Antibody(ies):	ck all that apply: gns of hemolysis pulin test (DAT) , clinically-significant antibodies en with newly identified RBC all (check all that apply) Chills/rigors Blood pressure decrease Edema Other rash Disseminated intravascular Abdominal pain	against red blood cells oantibody Fever Shock Flushing Pruritus (itching) coagulation Hemogl pain Flank pain Hemoglobinuria	☐ Jaundice ☐ Urticaria (hives) obinemia ☐ Infusion site pain ☐ Oliguria m ☐ Cough

	NI	H	S	Ν
NATION SAF	NAL H			

*Severity
Since this is by definition a reaction with no clinical symptoms, severity of the reaction cannot be graded.
Not determined
 *Imputability Which best describes the relationship between the transfusion and the reaction? Transfusion performed by your facility is the only possible cause for seroconversion. The patient has other exposures (e.g. transfusion by another facility or pregnancy) that could explain seroconversion, but transfusion by your facility is the most likely cause. The patient was transfused by your facility, but other exposures are present that most likely explain seroconversion. Evidence is clearly in favor of a cause other than the transfusion, but transfusion cannot be excluded. There is conclusive evidence beyond reasonable doubt of a cause other than the transfusion. The relationship between the adverse reaction and the transfusion is unknown or not stated. Did the transfusion occur at your facility? YES NO When was the new alloantibody identified? Occurred between 24 hours and 28 days after cessation of transfusion Occurred less than 24 hours after cessation of transfusion OR greater than 28 days after cessation of transfusion
No new antibody was identified
Module-generated Designations NOTE: Designations for case definition, severity, and imputability will be automatically assigned in the NHSN application based on responses in the corresponding investigation results section above. *Do you agree with the case definition designation? \[YES \] NO
^Please indicate your designation *Do you agree with the severity designation? ^Please indicate your designation
*Do you agree with the <i>imputability</i> designation?
Patient Treatment
Did the patient receive treatment for the transfusion reaction? YES NO UNKNOWN If yes, select treatment(s): Medication (Select the type of medication) Did the patient (Select the type of medication) Image: Antipyretics Antihistamines Inotropes/Vasopressors Bronchodilator Diuretics Image: Image: Antibiotics Image:
Volume resuscitation (Intravenous colloids or crystalloids)
 Respiratory support (Select the type of support) Mechanical ventilation Noninvasive ventilation Oxygen Renal replacement therapy (Select the type of therapy)
Hemodialysis Peritoneal Continuous Veno-Venous Hemofiltration CDC 57.310 Rev.2, v9.2 Page 3 of 5

NATIONAL HEALT SAFETY NETW	SN Incare York				OMB No. Exp. Date:	m Approved . 0920-0666 12/31/2026 dc.gov/nhsn
Den Phle	botomy					
	•					
Outcome						
Cause	Death:/ recipient died, relation Definite	e 🗌 Possibl	ion to death: le	Minor or no sed		
Was an	autopsy performed?	Yes	□ No			
Component	Details cular unit implicated	tin (i o rosno	nsible for) the	dvorso		
reaction?		ini (i.e., respc		auvei se	Yes No [N/A
Transfusion Start and End Date/Time	*Component code (check system used)	Amount transfused at reaction onset	^A Unit number (Required for Infection and TRALI)	*Unit expiration Date/Time	*Blood group of unit	Implic ated Unit?
^IMPLICATED	UNIT					-
// ::	☐ ISBT-128 ☐ Codabar	Entire unit		//	□ A- □ A+ □ B-	Y
// :		mL		:	□B+ □AB- □AB+ □O- □O+ □N/A	
// : // :	☐ ISBT-128 ☐ Codabar —————————	Entire unit Partial unit mL	 	//	□ A- □ A+ □ B- □B+ □ AB- □ AB+ □ O- □ O+ □ N/A	N
Custom Field	ds					
Label			Label			
		·/			//	
Comments						

